Invasive candidiasis in the ICU: Prophylaxis versus preemptive treatment

Current Infectious Disease Reports

Volumn 10, Issue 6, 2008, Pages 454-458

  Rotstein, Coleman ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; BETA GLUCAN; BIOLOGICAL MARKER; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; PLACEBO; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; CANDIDA; CANDIDEMIA; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DISEASE MARKER; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FUNGAL COLONIZATION; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; LENGTH OF STAY; LIVER TRANSPLANTATION; LOADING DRUG DOSE; NONHUMAN; PATIENT SELECTION; PREEMPTIVE ANTIFUNGAL THERAPY; REVIEW; RISK FACTOR; SERODIAGNOSIS; UNSPECIFIED SIDE EFFECT;

EID: 63249132900     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-008-0074-z     Document Type: Review

References (36)

1. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
2. Wisplinghoff H, Bischoff T, Tallent SM, et al.: Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317.
3. Azoulay E, Timsit J-F, Tafflet M, et al.: Candida colonization of the respiratory tree and subsequent Pseudomonas ventilator-associated pneumonia. Chest 2006, 129:110-117.
4. Clark TA, Slavinski SA, Morgan J, et al.: Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol 2004, 42:4468-4472.
5. Sanchez V, Vazquez JA, Barth-Jones D, et al.: Nosocomial acquisition of Candida parapsilosis: An epidemiologic study. Am J Med 1993, 94:577-582.
6. Vazquez JA, Sanchez V, Dmuchowski C, et al.: Nosocomial acquisition of Candida albicans: An epidemiologic study. J Infect Dis 1993, 168:195-201.
7. Doi M, Homma M, Inaguchi S, et al.: Strain relatedness of Candida albicans strains isolated from children with leukemia and their bedside parents. J Clin Microbiol 1994, 32:2253-2259.
8. Tortorano AM, Peman J, Bernhardt H, et al.: Epidemiology of candidaemia in Europe: Results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23:317-322.
9. Hadley S, Lee WW, Ruthazer R, Nasraway SA Jr: Candidemia as a cause of septic shock and multiple organ failure in non-immunocompromised patients. Crit Care Med 2002, 30:1808-1814.
10. Beck-Sagué C, Jarvis WR: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993, 167:1247-1251.
11. Wey SB, Mori M, Pfaller MA, et al.: Risk factors for hospital-acquired candidemia. A matched case-control study. Archiv Intern Med 1989, 149:2349-2353.
12. Komshian SV, Uwaydah AK, Sobel JD, Crane LR: Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: Frequency, characteristics, and valuation of factors influencing outcome. Rev Infect Dis 1989, 11:379-390.
13. Winston DJ, Emmanouilides C, Busuttil RW: Infections in liver transplant recipients. Clin Infect Dis 1995, 21:1077-1089.
14. Pittet D, Monod M, Suter PM, et al.: Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994: 220:751-758.
15. Zaoutis TE, Argon T, Chu J, et al.: The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis. Clin Infect Dis 2005, 41:1232-1239.
16. Bougnoux ME, Kac G, Aegerter P, et al.: CandiRea Study Group: Candidemia and candiduria in critically ill patients admitted to intensive care units in France: Incidence, molecular diversity, management and outcome. Intensive Care Med 2008, 34:292-299.
17. Olaechea PM, Palomar M, Léon-Gil C, et al.: Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis 2004, 23:323-330.
18. Bassetti M, Righi E, Costa A, et al.: Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006, 6:21.
19. Pappas PG, Rex JH, Sobel JD, et al.: Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38:161-189.
20. Rex JH, Sobel JD: Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001, 32:1191-1200.
21. Savino JA, Agarwal N, Wry P, et al.: Routine prophylactic antifungal agents (clotrimazole, ketoconazole and nystatin) in nontransplant/ nonburned critically ill surgical and trauma patients. J Trauma 1994, 36:20-25.
22. Ables A, Blumer N, Valginis G, et al.: Fluconazole prophylaxis of severe Candida infection in trauma and postsurgical patients: A prospective, double-blind, randomized, placebo-controlled trial. Infect Dis Clin Pract 2000, 9:169-175.
23. Charles PE, Dalle F, Gube H, et al.: Candida spp. colonization significance in critically ill medical patients: A prospective study. Intensive Care Med 2005, 31:393-400.
24. Petri MG, Konig J, Moecke HP, et al.: Epidemiology of invasive mycosis in ICU patients: A prospective multicenter study in 435 non-neutropenic patients. Intensive Care Med 1997, 23:317-325.
25. Pelz RK, Lipsett PA, Swoboda M, et al.: The diagnostic value of fungal surveillance cultures in critically ill patients. Surg Infect (Larchmt) 2000, 1:273-281.
26. Stephan F, Bah MS, Desterke C, et al.: Molecular diversity and routes of colonization of Candida albicans in a surgical intensive care unit as studied using microsatellite markers. Clin Infect Dis 2002, 35:1477-1483.
27. Cruciani M, de Lalla F, Mengoli C: Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: A systematic review and meta-analysis. Intensive Care Med 2005, 31:1479-1487.
28. Playford EG, Webster AC, Sorrell TC, Craig JC: Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev 2006, 25:CD0049.
29. Shorr AF, Chung K, Jackson WL, et al.: Fluconazole prophylaxis in critically ill surgical patients: A meta-analysis. Crit Care Med 2005, 33:1928-1935.
30. Cruciani M, Mengoli C, Malena M, et al.: Antifungal prophylaxis in liver transplant patients: A systematic review and meta-analysis. Liver Transpl 2006, 12:850-858.
31. Playford EG, Webster AC, Sorrell TC, Craig JC: Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 2006, 25:549-561.
32. Singh N: Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design. Clin Infect Dis 2004, 39:S200-S206.
33. Piarroux R, Grenouillet F, Balvay P, et al.: Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004, 32:2443-2449.
34. Takesue Y, Kakehashi M, Ohge J, et al.: Combined assessment of beta-J-glucan and degree of Candida colonization before starting empiric therapy for candidiasis in surgical patients. World J Surg 2004, 28:625-630.
35. Ostrosky-Zeichner L, Alexander B, Kett DH, et al.: Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005, 41:654-659.
36. McMullan R, Metwally L, Coyle PV, et al.: A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in non-neutropenic, critically ill adults. Clin Infect Dis 2008, 46:890-896.